18 unchanged sentences
Change in fair value of acquisition-related contingent consideration
+Added: Collaboration loss sharing
Total costs and expenses
9 unchanged sentences
Shares used in computing net income (loss) per share:
−Removed: (1) 2019, 2018, 2017 and 2016 product revenues, net, relate to our product sales of JAKAFI and product sales of ICLUSIG from the date of acquisition on June 1, 2016.
−Removed: 2015 product revenues, net, relate to our product sales of JAKAFI.
+Added: (1) 2020 product revenues, net, include our product sales of JAKAFI, ICLUSIG and PEMAZYRE.
+Added: 2019, 2018, 2017 and 2016 product revenues, net, relate to our product sales of JAKAFI and ICLUSIG from the date of acquisition on June 1, 2016.
+Added: (2) 2020 product royalty revenues relate to Novartis net sales of TABRECTA worldwide, Novartis net sales of JAKAVI outside of the United States and Lilly net sales of OLUMIANT outside of the United States.
2019, 2018 and 2017 product royalty revenues relate to Novartis net sales of JAKAVI outside of the United States and Lilly net sales of OLUMIANT outside of the United States.
−Removed: 2016 and 2015 product royalty revenues relate to Novartis net sales of JAKAVI outside the United States.
+Added: 2016 product royalty revenues relate to Novartis net sales of JAKAVI outside the United States.
+Added: (3) 2020 milestone and contract revenues relate to our collaborative research and license agreements with Novartis, Lilly and Innovent.
2019 milestone and contract revenues relate to our collaborative research and license agreements with Innovent and Zai Lab.
12 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.